Large Scale Biomarker Discovery: Next-Gen Mass Spectrometry Profiling to Accelerate Drug Development
Now On Demand | Hosted by AAPS
Circulating biomarker discovery is a critical component of the drug discovery process, identifying markers that improve our understanding of complex disease processes and enable personalization of therapy, evaluation of target engagement, clinical trial enrichment, and more. To date, however, large scale discovery of circulating biomarkers has been limited by bioanalytical constraints that preclude assessment of the thousands of circulating factors on a population scale.
In this session, Sapient’s Founder and CEO Dr. Mo Jain discusses a next-generation, high throughput mass spectrometry-based platform that enables rapid population-level discovery of circulating biomarkers. He further highlights a series of real-world case studies in which these technologies have been applied to identify sensitive and specific biomarkers of biological processes, disease progression, and drug responsiveness to advance and accelerate drug development pipelines.
